Global Drug Eluting Beads

Drug Eluting Beads Comprehensive Study by Type (LC Beads, QuadraSpheres, Oncozene Beads), Application (Hospitals, Specialized Clinics, Ambulatory Surgical Centers, Research Centers), Drug (Doxorubicin, Irinotecan, Idarubicin, Others), Diseases (Metastatic Colon Cancer, Pancreatic Cancer, Liver Cancer, Others) Players and Region - Global Market Outlook to 2028

Drug Eluting Beads Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled

Report Objectives / Segmentation Covered

By Type
  • LC Beads
  • QuadraSpheres
  • Oncozene Beads
By Application
  • Hospitals
  • Specialized Clinics
  • Ambulatory Surgical Centers
  • Research Centers
By Drug
  • Doxorubicin
  • Irinotecan
  • Idarubicin
  • Others

By Diseases
  • Metastatic Colon Cancer
  • Pancreatic Cancer
  • Liver Cancer
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Old Age Population in the World
      • 3.2.2. Emerging Number of The Liver Disease
    • 3.3. Market Challenges
      • 3.3.1. Stiff Competition in Drug Eluting Beads Market
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption of Drug Eluting Beads Technology for Transarterial Chemoembolization
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drug Eluting Beads, by Type, Application, Drug, Diseases and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Drug Eluting Beads (Value)
      • 5.2.1. Global Drug Eluting Beads by: Type (Value)
        • 5.2.1.1. LC Beads
        • 5.2.1.2. QuadraSpheres
        • 5.2.1.3. Oncozene Beads
      • 5.2.2. Global Drug Eluting Beads by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialized Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
        • 5.2.2.4. Research Centers
      • 5.2.3. Global Drug Eluting Beads by: Drug (Value)
        • 5.2.3.1. Doxorubicin
        • 5.2.3.2. Irinotecan
        • 5.2.3.3. Idarubicin
        • 5.2.3.4. Others
      • 5.2.4. Global Drug Eluting Beads by: Diseases (Value)
        • 5.2.4.1. Metastatic Colon Cancer
        • 5.2.4.2. Pancreatic Cancer
        • 5.2.4.3. Liver Cancer
        • 5.2.4.4. Others
      • 5.2.5. Global Drug Eluting Beads Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Drug Eluting Beads (Price)
      • 5.3.1. Global Drug Eluting Beads by: Type (Price)
  • 6. Drug Eluting Beads: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boston Scientific Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merit Medical Systems (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biocompatibles (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medtronic (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Surefire Medical, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Drug Eluting Beads Sale, by Type, Application, Drug, Diseases and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Drug Eluting Beads (Value)
      • 7.2.1. Global Drug Eluting Beads by: Type (Value)
        • 7.2.1.1. LC Beads
        • 7.2.1.2. QuadraSpheres
        • 7.2.1.3. Oncozene Beads
      • 7.2.2. Global Drug Eluting Beads by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialized Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
        • 7.2.2.4. Research Centers
      • 7.2.3. Global Drug Eluting Beads by: Drug (Value)
        • 7.2.3.1. Doxorubicin
        • 7.2.3.2. Irinotecan
        • 7.2.3.3. Idarubicin
        • 7.2.3.4. Others
      • 7.2.4. Global Drug Eluting Beads by: Diseases (Value)
        • 7.2.4.1. Metastatic Colon Cancer
        • 7.2.4.2. Pancreatic Cancer
        • 7.2.4.3. Liver Cancer
        • 7.2.4.4. Others
      • 7.2.5. Global Drug Eluting Beads Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Drug Eluting Beads (Price)
      • 7.3.1. Global Drug Eluting Beads by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drug Eluting Beads: by Type(USD Million)
  • Table 2. Drug Eluting Beads LC Beads , by Region USD Million (2017-2022)
  • Table 3. Drug Eluting Beads QuadraSpheres , by Region USD Million (2017-2022)
  • Table 4. Drug Eluting Beads Oncozene Beads , by Region USD Million (2017-2022)
  • Table 5. Drug Eluting Beads: by Application(USD Million)
  • Table 6. Drug Eluting Beads Hospitals , by Region USD Million (2017-2022)
  • Table 7. Drug Eluting Beads Specialized Clinics , by Region USD Million (2017-2022)
  • Table 8. Drug Eluting Beads Ambulatory Surgical Centers , by Region USD Million (2017-2022)
  • Table 9. Drug Eluting Beads Research Centers , by Region USD Million (2017-2022)
  • Table 10. Drug Eluting Beads: by Drug(USD Million)
  • Table 11. Drug Eluting Beads Doxorubicin , by Region USD Million (2017-2022)
  • Table 12. Drug Eluting Beads Irinotecan , by Region USD Million (2017-2022)
  • Table 13. Drug Eluting Beads Idarubicin , by Region USD Million (2017-2022)
  • Table 14. Drug Eluting Beads Others , by Region USD Million (2017-2022)
  • Table 15. Drug Eluting Beads: by Diseases(USD Million)
  • Table 16. Drug Eluting Beads Metastatic Colon Cancer , by Region USD Million (2017-2022)
  • Table 17. Drug Eluting Beads Pancreatic Cancer , by Region USD Million (2017-2022)
  • Table 18. Drug Eluting Beads Liver Cancer , by Region USD Million (2017-2022)
  • Table 19. Drug Eluting Beads Others , by Region USD Million (2017-2022)
  • Table 20. South America Drug Eluting Beads, by Country USD Million (2017-2022)
  • Table 21. South America Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 22. South America Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 23. South America Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 24. South America Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 25. Brazil Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 26. Brazil Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 27. Brazil Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 28. Brazil Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 29. Argentina Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 30. Argentina Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 31. Argentina Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 32. Argentina Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 33. Rest of South America Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 34. Rest of South America Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 35. Rest of South America Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 36. Rest of South America Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 37. Asia Pacific Drug Eluting Beads, by Country USD Million (2017-2022)
  • Table 38. Asia Pacific Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 39. Asia Pacific Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 40. Asia Pacific Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 41. Asia Pacific Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 42. China Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 43. China Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 44. China Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 45. China Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 46. Japan Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 47. Japan Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 48. Japan Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 49. Japan Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 50. India Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 51. India Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 52. India Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 53. India Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 54. South Korea Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 55. South Korea Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 56. South Korea Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 57. South Korea Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 58. Taiwan Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 59. Taiwan Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 60. Taiwan Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 61. Taiwan Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 62. Australia Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 63. Australia Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 64. Australia Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 65. Australia Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 70. Europe Drug Eluting Beads, by Country USD Million (2017-2022)
  • Table 71. Europe Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 72. Europe Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 73. Europe Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 74. Europe Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 75. Germany Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 76. Germany Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 77. Germany Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 78. Germany Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 79. France Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 80. France Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 81. France Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 82. France Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 83. Italy Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 84. Italy Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 85. Italy Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 86. Italy Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 87. United Kingdom Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 88. United Kingdom Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 89. United Kingdom Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 90. United Kingdom Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 91. Netherlands Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 92. Netherlands Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 93. Netherlands Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 94. Netherlands Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 95. Rest of Europe Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 96. Rest of Europe Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 97. Rest of Europe Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 98. Rest of Europe Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 99. MEA Drug Eluting Beads, by Country USD Million (2017-2022)
  • Table 100. MEA Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 101. MEA Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 102. MEA Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 103. MEA Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 104. Middle East Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 105. Middle East Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 106. Middle East Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 107. Middle East Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 108. Africa Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 109. Africa Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 110. Africa Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 111. Africa Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 112. North America Drug Eluting Beads, by Country USD Million (2017-2022)
  • Table 113. North America Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 114. North America Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 115. North America Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 116. North America Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 117. United States Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 118. United States Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 119. United States Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 120. United States Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 121. Canada Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 122. Canada Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 123. Canada Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 124. Canada Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 125. Mexico Drug Eluting Beads, by Type USD Million (2017-2022)
  • Table 126. Mexico Drug Eluting Beads, by Application USD Million (2017-2022)
  • Table 127. Mexico Drug Eluting Beads, by Drug USD Million (2017-2022)
  • Table 128. Mexico Drug Eluting Beads, by Diseases USD Million (2017-2022)
  • Table 129. Drug Eluting Beads: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Drug Eluting Beads: by Type(USD Million)
  • Table 136. Drug Eluting Beads LC Beads , by Region USD Million (2023-2028)
  • Table 137. Drug Eluting Beads QuadraSpheres , by Region USD Million (2023-2028)
  • Table 138. Drug Eluting Beads Oncozene Beads , by Region USD Million (2023-2028)
  • Table 139. Drug Eluting Beads: by Application(USD Million)
  • Table 140. Drug Eluting Beads Hospitals , by Region USD Million (2023-2028)
  • Table 141. Drug Eluting Beads Specialized Clinics , by Region USD Million (2023-2028)
  • Table 142. Drug Eluting Beads Ambulatory Surgical Centers , by Region USD Million (2023-2028)
  • Table 143. Drug Eluting Beads Research Centers , by Region USD Million (2023-2028)
  • Table 144. Drug Eluting Beads: by Drug(USD Million)
  • Table 145. Drug Eluting Beads Doxorubicin , by Region USD Million (2023-2028)
  • Table 146. Drug Eluting Beads Irinotecan , by Region USD Million (2023-2028)
  • Table 147. Drug Eluting Beads Idarubicin , by Region USD Million (2023-2028)
  • Table 148. Drug Eluting Beads Others , by Region USD Million (2023-2028)
  • Table 149. Drug Eluting Beads: by Diseases(USD Million)
  • Table 150. Drug Eluting Beads Metastatic Colon Cancer , by Region USD Million (2023-2028)
  • Table 151. Drug Eluting Beads Pancreatic Cancer , by Region USD Million (2023-2028)
  • Table 152. Drug Eluting Beads Liver Cancer , by Region USD Million (2023-2028)
  • Table 153. Drug Eluting Beads Others , by Region USD Million (2023-2028)
  • Table 154. South America Drug Eluting Beads, by Country USD Million (2023-2028)
  • Table 155. South America Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 156. South America Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 157. South America Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 158. South America Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 159. Brazil Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 160. Brazil Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 161. Brazil Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 162. Brazil Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 163. Argentina Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 164. Argentina Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 165. Argentina Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 166. Argentina Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 167. Rest of South America Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 168. Rest of South America Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 169. Rest of South America Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 170. Rest of South America Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 171. Asia Pacific Drug Eluting Beads, by Country USD Million (2023-2028)
  • Table 172. Asia Pacific Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 173. Asia Pacific Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 174. Asia Pacific Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 175. Asia Pacific Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 176. China Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 177. China Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 178. China Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 179. China Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 180. Japan Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 181. Japan Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 182. Japan Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 183. Japan Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 184. India Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 185. India Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 186. India Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 187. India Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 188. South Korea Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 189. South Korea Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 190. South Korea Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 191. South Korea Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 192. Taiwan Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 193. Taiwan Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 194. Taiwan Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 195. Taiwan Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 196. Australia Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 197. Australia Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 198. Australia Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 199. Australia Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 200. Rest of Asia-Pacific Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 204. Europe Drug Eluting Beads, by Country USD Million (2023-2028)
  • Table 205. Europe Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 206. Europe Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 207. Europe Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 208. Europe Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 209. Germany Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 210. Germany Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 211. Germany Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 212. Germany Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 213. France Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 214. France Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 215. France Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 216. France Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 217. Italy Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 218. Italy Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 219. Italy Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 220. Italy Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 221. United Kingdom Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 222. United Kingdom Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 223. United Kingdom Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 224. United Kingdom Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 225. Netherlands Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 226. Netherlands Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 227. Netherlands Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 228. Netherlands Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 229. Rest of Europe Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 230. Rest of Europe Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 231. Rest of Europe Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 232. Rest of Europe Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 233. MEA Drug Eluting Beads, by Country USD Million (2023-2028)
  • Table 234. MEA Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 235. MEA Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 236. MEA Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 237. MEA Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 238. Middle East Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 239. Middle East Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 240. Middle East Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 241. Middle East Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 242. Africa Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 243. Africa Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 244. Africa Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 245. Africa Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 246. North America Drug Eluting Beads, by Country USD Million (2023-2028)
  • Table 247. North America Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 248. North America Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 249. North America Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 250. North America Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 251. United States Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 252. United States Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 253. United States Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 254. United States Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 255. Canada Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 256. Canada Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 257. Canada Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 258. Canada Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 259. Mexico Drug Eluting Beads, by Type USD Million (2023-2028)
  • Table 260. Mexico Drug Eluting Beads, by Application USD Million (2023-2028)
  • Table 261. Mexico Drug Eluting Beads, by Drug USD Million (2023-2028)
  • Table 262. Mexico Drug Eluting Beads, by Diseases USD Million (2023-2028)
  • Table 263. Drug Eluting Beads: by Type(USD/Units)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drug Eluting Beads: by Type USD Million (2017-2022)
  • Figure 5. Global Drug Eluting Beads: by Application USD Million (2017-2022)
  • Figure 6. Global Drug Eluting Beads: by Drug USD Million (2017-2022)
  • Figure 7. Global Drug Eluting Beads: by Diseases USD Million (2017-2022)
  • Figure 8. South America Drug Eluting Beads Share (%), by Country
  • Figure 9. Asia Pacific Drug Eluting Beads Share (%), by Country
  • Figure 10. Europe Drug Eluting Beads Share (%), by Country
  • Figure 11. MEA Drug Eluting Beads Share (%), by Country
  • Figure 12. North America Drug Eluting Beads Share (%), by Country
  • Figure 13. Global Drug Eluting Beads: by Type USD/Units (2017-2022)
  • Figure 14. Global Drug Eluting Beads share by Players 2022 (%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 17. Boston Scientific Corporation (United States) Revenue: by Geography 2022
  • Figure 18. Merit Medical Systems (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merit Medical Systems (United States) Revenue: by Geography 2022
  • Figure 20. Biocompatibles (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Biocompatibles (United Kingdom) Revenue: by Geography 2022
  • Figure 22. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Medtronic (Ireland) Revenue: by Geography 2022
  • Figure 24. Surefire Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Surefire Medical, Inc. (United States) Revenue: by Geography 2022
  • Figure 26. Global Drug Eluting Beads: by Type USD Million (2023-2028)
  • Figure 27. Global Drug Eluting Beads: by Application USD Million (2023-2028)
  • Figure 28. Global Drug Eluting Beads: by Drug USD Million (2023-2028)
  • Figure 29. Global Drug Eluting Beads: by Diseases USD Million (2023-2028)
  • Figure 30. South America Drug Eluting Beads Share (%), by Country
  • Figure 31. Asia Pacific Drug Eluting Beads Share (%), by Country
  • Figure 32. Europe Drug Eluting Beads Share (%), by Country
  • Figure 33. MEA Drug Eluting Beads Share (%), by Country
  • Figure 34. North America Drug Eluting Beads Share (%), by Country
  • Figure 35. Global Drug Eluting Beads: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Boston Scientific Corporation (United States)
  • Merit Medical Systems (United States)
  • Biocompatibles (United Kingdom)
  • Medtronic (Ireland)
  • Surefire Medical, Inc. (United States)
Additional players considered in the study are as follows:
BTG International Inc. (United Kingdom) , CeloNova. (United States) , Terumo Medical Corporation (United States)
Select User Access Type

Key Highlights of Report


Dec 2023 234 Pages 84 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Drug Eluting Beads Quantitative research analysis
Global Drug Eluting Beads Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Drug Eluting Beads Report?

Have a Query? Click Here

Other Related Reports

Breast Cancer Monoclonal Antibodies Comprehensive Study by Type (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies), Application (Hospitals, Retail Pharm...
$ 3500
Sotalol Drug Comprehensive Study by Application (Ventricular Arrhythmias, Atrial Fibrillation/Flutter, Supraventricular Arrhythmias), Distribution Channel (Sales Channel Hospital Pharmacies, Drug Sto...
$ 3650
Eye Infections Treatment Comprehensive Study by Type (Gels and Creams, Eye Drops, Drug), Application (Ophthalmology Clinics, Hospitals, Others), Eye Infection (Conjunctivitis or Pink Eye, Viral Kerat...
$ 3750
Allopurinol Tablets Comprehensive Study by Type (100 mg, 300 mg), Application (Healthcare Industry, Hospitals), Distribution Channel (Hospitals, Pharma Retail, Clinics, Others), Side Effects (Nausea,...
$ 3350
Urethritis Drugs Comprehensive Study by Type (Gonococcal Urethritis, Non gonococcal Urethritis), End-users (Hospitals and Clinics, Research and Academics, Others), Drugs Treatment (Antivirals, Anti-B...
$ 3800
Anti-Venom Comprehensive Study by Type (Snake Anti-Venom, Scorpion Anti-Venom, Spider Anti-Venom, Others), Mode of Action (Cytotoxic, Neurotoxic, Haemotoxic, Cardiotoxic, Myotoxic, Others), Antivenom...
$ 3750